visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone |
Data: | 2022 |
Resum: | Cerebrospinal fluid (CSF) Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio are markers of amyloid pathology, but previous studies suggest that their levels might be influenced by additional pathophysiological processes. To compare Aβ1-42 and the Aβ1-42/Aβ1-40 ratio in CSF in different neurodegenerative disorders and study their association with other biomarkers (tTau, pTau181, and NfL) and with cognitive and functional progression. We included all participants from the Sant Pau Initiative on Neurodegeneration (SPIN) with CSF Aβ1-42 and Aβ1-42/Aβ1-40. Participants had diagnoses of Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal lobar degeneration-related syndromes, non-neurodegenerative conditions, or were cognitively normal. We classified participants as "positive" or "negative" according to each marker. We compared CSF levels of tTau, pTau181, and NfL between concordant and discordant groups through ANCOVA and assessed differences in cognitive (MMSE, FCSRT) and functional (GDS, CDR-SOB) progression using Cox regression and linear-mixed models. In the 1791 participants, the agreement between Aβ1-42 and Aβ1-42/Aβ1-40 was 78. 3%. The Aβ1-42/Aβ1-40 ratio showed a stronger correlation with tTau and pTau181 than Aβ1-42 and an agreement with tTau and pTau181 of 73. 1% and 77. 1%, respectively. Participants with a low Aβ1-42/Aβ1-40 ratio showed higher tTau and pTau181 and worse cognitive and functional prognosis, regardless of whether they were positive or negative for Aβ1-42. The results were consistent across stages, diagnostic categories, and use of different cutoffs. Although Aβ1-42 and Aβ1-42/Aβ1-40 are considered markers of the same pathophysiological pathway, our findings provide evidence favoring the use of the Aβ1-42/Aβ1-40 ratio in clinical laboratories in the context of AD. The online version contains supplementary material available at 10. 1186/s13195-022-00967-z. |
Ajuts: | Instituto de Salud Carlos III PI14/01126 Instituto de Salud Carlos III PI17/01019 Instituto de Salud Carlos III PI20/01473 Instituto de Salud Carlos III PI13/01532 Instituto de Salud Carlos III PI16/01825 Instituto de Salud Carlos III PI18/00335 Instituto de Salud Carlos III PI18/00435 Instituto de Salud Carlos III INT19/00016 Instituto de Salud Carlos III PI17/01896 Instituto de Salud Carlos III AC19/00103 Agència de Gestió d'Ajuts Universitaris i de Recerca SLT006/17/125 Agència de Gestió d'Ajuts Universitaris i de Recerca SLT006/17/119 Agència de Gestió d'Ajuts Universitaris i de Recerca SLT002/16/408 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-547 |
Nota: | Altres ajuts: Fundació La Marató: 20141210, 044412, 20142610 |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Matèria: | Amyloid ; Aβ1-40 ; Aβ1-42 ; Cerebrospinal fluid ; Tau ; Biomarkers |
Publicat a: | Alzheimer's research & therapy, Vol. 14 (february 2022) , ISSN 1758-9193 |
11 p, 10.9 MB |